UAB GlaxoSmithKline Lietuva

UAB "GlaxoSmithKline Lietuva" is the Lithuanian subsidiary of GSK plc (formerly GlaxoSmithKline), a British multinational biopharmaceutical company focused on vaccines and specialty medicines. The company operates in Lithuania primarily as a marketing authorization holder representative, distributor, and medical affairs organization for GSK’s pharmaceutical and vaccine portfolio.

Company Overview

Legal name: UAB "GlaxoSmithKline Lietuva"
Country: Lithuania
Industry sector: Pharmaceuticals and Vaccines (Biopharma)
Founding in Lithuania: The entity operates in Lithuania since the late 1990s–early 2000s, following the global merger of Glaxo Wellcome and SmithKline Beecham in 2000; the precise local incorporation date for UAB "GlaxoSmithKline Lietuva" is not available in the sources consulted.
Headquarters (Lithuania): Vilnius (exact registered office address listed below when available)

Legal Information

Įmonės kodas (company code): Not available in the sources consulted within this dataset. Typically obtainable from Registrų centras (Lithuanian Centre of Registers).
PVM kodas (VAT code): Not available in the sources consulted; generally formatted as LT + company code for VAT-registered entities, verifiable via VMI (State Tax Inspectorate) VAT registry.
Official website: https://www.gsk.com
Local contact page: https://www.gsk.com/contact-us/worldwide/ (see Lithuania section)
Email address: Not publicly listed in the sources consulted; GSK usually provides country-specific contact forms or emails via its worldwide contact page.
Registered office address: Not available in the sources consulted; typically published in Registrų centras and on business directories such as Rekvizitai.lt.
Phone number: Not publicly listed in the sources consulted; often available on GSK’s Lithuania contact page or in business directories.

Note: For definitive legal identifiers (įmonės kodas, PVM kodas), the authoritative source is Registrų centras and the VMI VAT registry.

Business Operations

Main products and therapeutic areas:
- Vaccines: Preventive vaccines across infectious diseases (e.g., influenza, HPV, shingles (Shingrix), meningococcal, and others approved in the EU). Availability in Lithuania is subject to local market authorizations and procurement/reimbursement decisions.
- Specialty medicines: Focus areas include HIV (through GSK’s majority-owned ViiV Healthcare), respiratory (e.g., inhaled therapies from the Ellipta portfolio), oncology (e.g., Jemperli/dostarlimab and other oncology assets approved in the EU), and immunology/inflammation.
- General medicines: Selected widely used medicines in respiratory, antibiotics, and other primary care areas.

Business model in Lithuania: UAB "GlaxoSmithKline Lietuva" acts as a local subsidiary handling regulatory liaison, pharmacovigilance compliance, medical affairs, professional education, tender participation (especially for vaccines), and commercial distribution via wholesalers to pharmacies, hospitals, and clinics. Price and reimbursement decisions are coordinated with Lithuanian authorities (e.g., Ministry of Health, National Health Insurance Fund) and the State Medicines Control Agency (VVKT).

Market position: GSK is among the leading multinational pharmaceutical companies in Lithuania, particularly strong in vaccines and certain specialty therapeutic areas. Market share fluctuates by segment (vaccines vs. prescription medicines) and year, depending on tenders and reimbursement listings.

History

Founding story and milestones:
- 2000: Globally, Glaxo Wellcome and SmithKline Beecham merge to form GlaxoSmithKline (GSK). Lithuanian operations consolidate around the new entity’s local presence.
- 2000s–2010s: Expansion of vaccine and prescription medicine portfolios in Lithuania, aligning with EU approvals and local tender/reimbursement frameworks.
- 2022: Global demerger of GSK’s consumer healthcare into Haleon plc; non-prescription consumer health brands were separated from GSK. In Lithuania, consumer health activities shifted under Haleon, while UAB "GlaxoSmithKline Lietuva" continued focusing on biopharma (vaccines and specialty medicines).
- 2023–2024: EU approvals and launches in RSV vaccines (Arexvy), oncology indications (e.g., Jemperli expansions), and HIV innovations (via ViiV Healthcare), with rollouts subject to Lithuanian regulatory and market access decisions.

Specific local corporate events (e.g., incorporation date changes, address updates) should be verified in Registrų centras historical records.

Financial Information

Revenue: As a privately held Lithuanian UAB subsidiary, detailed annual revenue figures are not published in global reports. Local financial statements may be filed with Lithuanian authorities and summarized on business directories; the precise revenue data was not available in the sources consulted.
Funding rounds: None; UAB "GlaxoSmithKline Lietuva" is a wholly owned corporate subsidiary of GSK plc and is funded internally.
Ownership structure: Indirectly wholly owned by GSK plc (United Kingdom). Some HIV portfolio activities are commercialized via ViiV Healthcare, a separate entity majority-owned by GSK.

Leadership and Management

Vadovai (executives): Lithuanian UABs typically have a general manager (direktorius) or country manager. The full names and current positions for UAB "GlaxoSmithKline Lietuva" executives were not available in the sources consulted for this profile.
Board members: Not publicly listed in the sources consulted. Lithuanian UAB corporate governance details (management, authorized signatories) are maintained by Registrų centras.

For authoritative, up-to-date names and roles, consult the Lithuanian Centre of Registers and GSK’s official contact materials.

Office Locations

Registered office: Vilnius, Lithuania (exact street address and postcode not available in the sources consulted).
Phone numbers for offices: Not available in the sources consulted.
Other offices: No additional Lithuanian locations publicly indicated in the sources consulted.

Note: Precise addresses and phone numbers are typically disclosed in Registrų centras and on GSK’s Lithuania contact page or in local business directories (e.g., Rekvizitai.lt).

Market Position

Competitors in Lithuania: Pfizer, Novartis, Sanofi, AstraZeneca, MSD (Merck Sharp & Dohme), Johnson & Johnson (Janssen), Roche, Bayer, Takeda, and other multinational and local pharma entities.
Competitive advantages: A leading global vaccine portfolio; strong specialty medicine pipeline; extensive clinical and medical affairs capabilities; robust pharmacovigilance and compliance systems; global scale supporting stable supply and tender performance.
Market share: Varies by therapeutic area and year; GSK is typically prominent in vaccines. Precise market share figures require access to IQVIA market audits or Lithuanian procurement/tender statistics and are not available in the sources consulted.

Recent Developments

Product and regulatory updates:
- EU-wide momentum in vaccines (e.g., RSV vaccine Arexvy for older adults, post-2023 approvals) with subsequent country-level access paths, potentially including Lithuania depending on local decisions.
- Oncology expansions (e.g., Jemperli/dostarlimab indications), subject to Lithuanian reimbursement and formulary processes.
- HIV treatment innovations via ViiV Healthcare (e.g., long-acting regimens), with availability depending on local approvals and procurement.
Corporate developments: Continuation of biopharma focus after the 2022 Haleon demerger; sustained investment in R&D globally and alignment of local portfolios with EU approvals.

For the latest Lithuanian-specific changes (tenders, reimbursement listings, safety communications), refer to VVKT publications and GSK’s country contact materials.

Contact Information

Official website: https://www.gsk.com
Worldwide contact page: https://www.gsk.com/contact-us/worldwide/ (navigate to Lithuania)
Email: Not publicly listed in the sources consulted; country-specific contact forms are provided via the worldwide page.
Registered office address (Lithuania): Not available in the sources consulted; check Registrų centras or Rekvizitai.lt for official address.
Telephone: Not publicly listed in the sources consulted.

Sources and References

- GSK plc official website and corporate materials: https://www.gsk.com
- GSK Worldwide Contact directory (country pages, including Lithuania): https://www.gsk.com/contact-us/worldwide/
- Lithuanian Centre of Registers (Registrų centras) — official registry for legal entities: https://www.registrucentras.lt
- State Tax Inspectorate (VMI) — VAT registry: https://www.vmi.lt
- Rekvizitai.lt — Lithuanian business directory (company profiles, legal identifiers, addresses): https://www.rekvizitai.lt
- Valstybinė vaistų kontrolės tarnyba (VVKT) — Lithuanian State Medicines Control Agency (product authorizations, safety notices): https://www.vvkt.lt
- GSK annual reports and investor materials (global strategy, pipeline, and approvals): https://www.gsk.com/en-gb/investors/

Important note: Specific Lithuanian legal identifiers (įmonės kodas, PVM kodas), executive names, and office phones were not available in the sources accessed for this profile. For definitive, current information, consult Registrų centras, VMI VAT registry, and GSK’s official Lithuania contact listings.